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ABSTRACT
This research focuses on the development of mononuclear platinum complexes; multinuclear platinum
complexes, both of which self assemble into micelles in the presence of water. This work also involved
the synthesis of a reverse micelle that allows for detection of water nanocrystals within a defined size
molecular envelope. The novel synthesis of these compounds allows for ligand substitution and the
creation of a library of compounds.
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CHAPTER 1:
INTRODUCTION AND LITERATURE REVIEW
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Mononuclear platinum complexes, multinuclear platinum complexes, and inverse micelle
synthesis are the main focus of this research. When speaking about platinum complexes, one
cannot leave out the amazing discovery of cisplatin.
As illustrated by Howell in his paper (1991), “Cis-Platin, discovered by B. Rosenberg, et.
al. in 1969 is nowadays one of the best and widely used antitumor agents in cancer
chemotherapy…Various attempts have been made to prepare future generation antitumor Pt
complexes, ameliorating severe toxicities” (pp. 127). Cisplatin has been renowned for years as
having been a leading anti-cancer drug. Here, some of the remarkable advances in cancer
research will be thoroughly discussed, with the advent of platinum-based drugs having had a
wondrous impact on science and coordination chemistry in general.
Cisplatin is favored by many in the biomedical sciences as the wonder drug that has
actively helped several people overcome cancer. Cisplatin is not just a miraculous drug in the
sense that it is currently being used against many forms of breast cancer, while it does kill
tumors, it does not cure people. Cisplatin is also miraculous in the sense that it has gone above
and beyond what was expected of it as a drug. Cisplatin has shattered the perceptions of what
could possibly be done in coordination chemistry.
Modern inorganic chemistry has faced the boondoggle of developing effective cancer
therapy drugs for years. However, it was not until cisplatin was discovered that scientists finally
got the idea to begin testing more platinum drugs. Other Pt complexes have begun to be
clinically tested and distributed over time. Not only that, but there are more and more
coordinated compounds that continue to be developed that have platinum bases, in order to
combat cancer and its ill effects.
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Certainly, the properties evidenced in cisplatin are germane to other sciences. Not as
stated by Gispert (2008), “Polynuclear transition metal chemistry is an area of modern science
whose interfaces with many disciplines have provided invaluable opportunities for crossing
boundaries both within and between the sciences of chemistry, physics, and biology. Indeed,
molecular multimetallic compounds have unusual and useful catalytic, optical, photochemical,
electronic, and magnetic properties” (pp. 129).
Other sciences are now realizing the value that this research has unearthed, particularly
with polynuclear compounds such as multinuclear platinum complexes. This will be discussed
later, second, along with mononuclear platinum complexes, first, and inverse micelle synthesis,
third.
Cisplatin is now considered one of the leading anti-cancer drugs currently being studied.
The value of this drug cannot go unnoticed. Without a doubt, chemists will be analyzing the
molecular make-up of this drug in order to replicate similar drugs. Physicians and bio-chemists
will want to know the make-up of cisplatin as well. They will want to be able to explain the
physics and the hard science of how cisplatin works. Biologists will want to know how cisplatin
affects the living organism and its cells. Biologists especially will need this information in order
to help other scientists excel in cancer research.
Ligands play a large role in how mononuclear platinum complexes are structured. Singh
(2002), “In coordination compounds, metals are surrounded by groups that are called ligands”,
they play a major role in the chemistry of metal complexes. The…groups that may surround a
metal atom or ion are …varied, but they may be broadly considered to be of two types: ligands
that bond to metal atoms or ions through carbon atoms, and ligands that do not” (pp. 88). A
ligand, in a mononuclear platinum complex—to illustrate the point—is much like the core of a
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mango. The middle of the structure has one single core (the ligand), while the rest of the
structure surrounds it (the molecules of Pt, platinum). The ligand, by definition, is basically the
glue that holds together the entire structure. Ligands are important because, without them, the
structure would not be able to be held together properly in place.
Sometimes ligand substitutions can occur. According to Choy (2003), “Platinum
complexes are characterized by slow rates of ligand substitution reactions compared with other
metal complexes. Evidence from Peter Stang's research supports this. Because of the slew
reactions involved in platinum drugs binding to DNA, other intracellular nucleophiles…may
compete with DNA for reaction” (pp. 47), this documented behavior gave cause for further study
of metal-ligand complex interactions as related to biological activities.
What this is saying is that, basically, when there are slow reactions when ligand
substitution happens, there are other parts between cells which may try to react faster. This
could be problematic, especially if one ligand is particularly slow in reacting in contrast with
another metal complex or other metal complexes. Ligands are a necessity. Without them there
would be much difficulty in trying to facilitate the structure of the mononuclear platinum
complex.
Many things can affect the platinum atom. In the works of Marusak, Doan, and
Cummings (2007), “Force fields for cis-platin binding to DNA have been aggressively
developed over the past 15 years.
Parameter refinements include the deviation of…bond[s] from the plane of the
coordinated purine, planarity of the platinum moiety…and charges of the Pt atom, [among other
things]” (pp. 151). Cisplatin is remarkable for many reasons, as well as other platinum-based
drugs. The benefits of these drugs will be discussed more in detail later on, as well as what
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cancer patients have to gain from this valuable research. A review of the literature includes
sections about mononuclear platinum square complexes, multinuclear platinum complexes, and
inverse micelle synthesis, as well as a discussion and conclusion.
Cisplatin is a very popular complex which is widely and used in current cancer treatment.
Mackay, Mackay, and Henderson (2002), “The most widely used drug in the Western world and
Japan for the treatment of cancer is a simple inorganic coordination complex…commonly known
as cisplatin. This drug is particularly effective in the treatment of solid tumors…Like a number
of other important scientific discoveries, [this was discovered by accident]” (pp. 559).
Cisplatin has proven to be very useful in treating cancer. This is why it has been labeled
as a “wonder” drug. The development of cisplatin as an anti-cancer drug has been enormous. It
has been widely researched across cultures and has been found to have excellent success in
treating cancer, as aforementioned. Some researchers are so biased in favor of cisplatin that they
do not want to test any new drugs. However, the bulk of the research goes against the idea that
one should not look for new therapies approaching miraculous results. The way that cancer is
treated deals with how the body reacts to chemicals. According to Kelland and Farrell (2000),
“Accumulation of a drug is the net effect of drug influx and efflux.
Since the first reports of accumulation defects in cells with acquired resistance to
cisplatin, much effort has been directed toward defining the mechanisms that cisplatin enters and
leaves cells. “These mechanisms have been difficult to pinpoint” (pp. 89).
The way cisplatin is absorbed by the body has much to do with how the body reacts to
having it in one’s system. Basically, cisplatin in one’s body changes the body chemistry.
Therefore, some patients experience sickness. Once one has cisplatin in the system, it can tend
to have an effect of build-up in the system. This could be helpful but it usually turns out to be
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harmful in some way. Cancer patients are famous for feeling nauseous as well as vomiting. This
is in part caused by the effects platinum-based drugs have on the body. Platinum is a naturallyoccurring element in the body, but too much of it being introduced into the body can make a
cancer patient sick. Because of the success of several types of drugs, this is fomenting new
research.
In the works of Lippert (1999), “The success of cisplatin and carboplatin in treating
cancer, combined with the intrinsic and acquired resistance of many tumors to traditional
platinum chemotherapy, has generated considerable interest in developing next-generation
platinum drugs. Since the discovery of the antitumor activity of cisplatin, researchers have
reported…thousands of platinum compounds (pp. 523).
The possibility that there are more platinum compounds available make this facet of
cancer research very exciting. The fact that there “could be” more potentially life-saving drugs
which just remain undiscovered is a possibility that scientists are continually considering. Since
there is no cure for cancer, cisplatin has proved close to being a cure. But researchers are still
not there yet.
While everyone would like to acknowledge that some kind of a cure has been found, still
this is not the case. Since Farrell’s discovery of platinum-based drugs’ effects in the ‘90s, many
researchers in this field of cancer research have begun rethinking they way they saw anti-cancer
drug therapy. Platinum complexes fight tumors effectively, which will be discussed in-depth in
the next two sections. According to Gielen and Tiekink (2005), “The mode of action of platinum
agents can also be considerably affected by means other than changing of chemical
structure…originally inactive compounds can be activated…after [being] delivered to the target
tumor cells or to their intracellular components, Platinum (IV) complexes represent one example
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of this expanding class of anti-tumor agents” (pp. 499). The way that the chemical structure of
platinum complexes is set up, they make perfect foils for targeting cancerous cells.
Knowing about different platinum complexes could be the breakthrough in solving the
mystery of the cure for cancer. Written in Gielen, Willem, and Wrackmeyer (2004), “It is widely
believed that the principal target of platinum anticancer agents in cells is DNA and the resulting
DNA lesions are responsible for their biological activities…some…evidences have indicated that
the attack of platinum complexes on other non-DNA cellular targets could… play roles in the
antitumor activity of platinum drugs” (pp. 169).
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CHAPTER 2:
MONONUCLEAR PLATINUM SQUARE COMPLEXES
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2.1 Summary
The synthesis of a novel class of mononuclear cis-Pt/Pd phospine complexes with long chain
lipids was accomplished. These compounds exhibit amphillic properties that allow them to self-assemble
in water as micelles and have remarkable physical properties such as high stability in water. Figure 2.1
shows the molecular structure of the compounds presented in this chapter.

Figure 2.1. Structure of cis-Pt/Pd complex where M=Pt or Pd and X=Lewis Base

Introduction

Mononuclear platinum square complexes have three distinct aspects about them: usually
they are square-planar; they effectively change the DNA of cells around them; and they are
distinctively different from polynuclear or multinuclear platinum complexes. Mononuclear
platinum square complexes are square-planar. This means that they basically have four atoms of
platinum surrounding one atom of a particular ligand. In research conducted by Wiberg, Wiberg,
and Holleman (2001), “Square planar complexes are formed especially readily by metal centers
with [a certain] electron configuration…[usually] low-spin and therefore diamagnetic…
Tetrahedral…complexes are paramagnetic with no unpaired electrons…only diamagnetic
complexes are allowed with square coordination” (pp. 1187). A ligand is some type of element
9

that basically is made up of the atom in the center of the complex. There are a few different
types of elements that could make up the central connecting ligand. The ligand is basically the
part of the complex that connects the whole complex together. Without the ligand, there would
be no bonding. Within the bonding of inorganic compounds, this is called coordination
chemistry. It is a branch of inorganic chemistry.
Metallopharmaceuticals is the branch of medicine that deals with inorganic metals being
placed into prescription drugs. What is important about the square-planar aspect follows shortly.
Basically, the firm structure of the square-planar model makes for an excellent example of what
is right with cancer research. This cannot go unnoticed. The square-planar model is a
structurally efficient model. Only four atoms of platinum are needed for every one atom of
ligand—whatever the element of that ligand might be.
As stated in Sykes (1994), “Deviations of each metal atom from the coordination plane
defined by the four donor atoms are taken as a plus value when the metal atoms deviate from the
coordination plane toward each other. It directly correlates with the difference
between…distances only when the complexes have an eclipsed configuration” (pp. 194).
Mononuclear platinum square complexes ultimately change the DNA of the cells around them.
This is what makes them so effective at combating cancer and this is why they should be studied
more.
Mononuclear platinum square complexes definitely are different from multinuclear
platinum complexes. Although researchers are not entirely sure, they have many good hunches
that multinuclear platinum complexes react differently than do their mononuclear counterparts.
In fact, in some parts of the research world in cancer research, the jury is out as to which
platinum complex is more effective. Right now, it seems as though there is still much interest in
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the mononuclear platinum square complex. Because of the fact that it only has one ligand, this
makes the mononuclear structure particularly desirable. Although small, a solid structure such as
the square-planar platinum complex is being studied in-depth to determine if it is indeed more
desirable than the multinuclear platinum complex.
Mononuclear platinum complexes are mainly distinctive from their multinuclear
counterparts exactly because of that they have different counts of atoms in their centers. While
mononuclear platinum square complexes have four atoms of platinum surrounding one atom of a
ligand, multinuclear platinum complexes may have several atoms of a ligand in the nucleus.
In Demeunynck, Bailly, and Wilson (2003), “[There is a] fundamental difference
between mononuclear and dinuclear platinum chemistry and biology—in the mononuclear case
cisplatin is active, while its’ direct isomer transplatin is antitumour-inactive…provid[ing] the
impetus for the studies of molecular mechanisms underlying these differences” (pp. 205).
Another distinct difference between mononuclear and multinuclear platinum complexes is the
fact that they each have varying rates of effectiveness at curing cancer. One is favored more
over the other in terms of its rate of efficiency in being able to eradicate cancer.
What happens is that, usually, the complex’s ability to bind with DNA is a key factor in
deciding whether it will bind to cancerous cells and then destroy them. The complex may have a
substitutionary ligand that may react quicker than another ligand. So, in taking all of these
matters into consideration, basically it depends upon the complex itself. If one ligand is reacting
to the DNA faster than another ligand, it is more important that that particular complex is used
(whichever one that is).
Substitutionary ligands become important to the project when one realizes that the fasteracting ligand will take place of the slower one. This can prove a major finding when conducting
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an experiment. Basically, the way DNA is affected by the mononuclear platinum complex
depends on a variety of factors. The quality of the platinum being used in the experiment could
definitely affect how fast an element would bond to its metal ion ligand. According to Van
Leeuwen (2004), “[R]ecent findings support a mononuclear platinum complex as the resting
state and active state of the platinum…catalyst” (pp. 377). Usually, platinum complexes tend to
be square-planar, as demonstrated in the research of Macintyre and Macintyre (1995), “Pt(II)
complexes are predominantly square planar…”
“Most platinum complexes are air- and moisture-stable, and can be handled
conventionally at ordinary temperatures” (pp. 2997). Crosslinking agents aid in the abetment of
cancer. Thus, tetrahedron complexes such as this one are very helpful in the destruction of
cancer cells. Written in Sigel and Sigel (2004), “Tetrafunctional complexes are also very
effective ternary DNA-protein crosslinking agents…” (pp. 274).
These complexes also change themselves relevant to their surroundings. According to
Dupont (2008), “Mononuclear…platinum complexes were mesomorphic…” (pp. 262).
Reactions within the mononuclear square platinum complexes are a highly sought-after research
topic. As documented in Screttas and Steele (2002), “[There is] a longstanding interest in the
kinetics and reaction of mechanisms of four-coordinate coordination and organometallic squareplanar complexes, especially those of platinum(II)” (pp. 208).
Sometimes tetrahedral complexes can become larger. In studies conducted by Gispert
(2008), “Very large ligands tend not to yield this geometry, and neither do very small ligands
favor it as they tend to increase the coordination number, giving rise to octahedral coordination”
(pp. 64). The research among platinum compounds is exploding. Written in Farrell (1999),
“During the last ten years,…a number of novel dinuclear Pt compounds [have been prepared],
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where two platinum-amine coordination units are linked by a variable length diamine linker, as
potential antitumor drugs… Extensively studied…new classes of platinum compounds [helped
one] understand the patterns of DNA modification [with respect to] cytotoxicity…” (pp. 125).

2.3 Goals and Objectives
The goal is to synthesize a novel class of cis-Pt/Pd phospine complexes with long chain lipids.
These compounds will exhibit amphiphillic properties that would allow them to self assemble in water as
a micelle.
2.4 Multi-step Synthesis
The synthesis of the mononuclear compounds presented here in was carried out according to the
following protocol:
Starting with palladium (II) chloride was reacted with 1.3 equivalents of cyclooctadiene in the
presence of dichloromethane at room temperature for 24 hours. The solution was then filtered using
gravity filtration. A bright yellow chalky solid was collected. The remaining solution was then rotoevaporated to extract any remaining product still in solution. The total yield was 82%. This gave a cis-Pd
complex with chlorine on one end and cyclooctadiene on the opposite. (figure. 2.2).

Figure 2.2 Synthesis of cid-Pd compound with cyclooctadiene
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In the second step, the cis-Pd complex was reacted with a phospine ligand that had four dodecyl
groups (C12H25) lipid chains attached. Because the phospine ligand was highly hygroscopic and in the
presence of air would oxidize, the synthesis had to be carried out under anaerobic conditions using argon
gas. The reaction vessel was prepared by using an acetone bath followed by one hour in the drying oven
at a constant temperature. The hot round bottom flask was then removed and set up immediately before
allowing it to cool and accumulate micro condensation. A septum was placed over the flask and one
syringe needle was inserted to act as ventilation, argon gas was then allowed to flow in via a second
syringe needle, since argon is heavier than oxygen, allowing it to flow freely into the reaction vessel for
about thirty minutes replaced a sufficient amount of oxygen in order to nearly eliminate the possibility for
premature oxidation. The cis-Pd /cyclooctadiene compound was reacted with the phospine ligand in a
1:21 ratio in the presence of chloroform and argon at room temperature for a 24 hour period. The
resulting solution was filtered under gravity filtration. A crystalline white solid was collected. The
filtrate was then rotoevaporated to obtain any product remaining in solution. The yield was 74%. The
resulting cis-Pd compound now has the phospine ligand with lipid chains opposite the two chlorines

Fig 2.3 Synthesis of cis-Pd complex with Phosphine ligand.
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The compound is then reacted with 2.4 equivalents of silver triflouromethane sulfonate in the
presence of chloroform for 24 hours to replace the chlorides for the triflates, which can be easily cleaved
in subsequent experiments. This reaction was done in a covered vessel to prevent light from
photoreacting the protecting group, as silver is photosensitive. The resulting product is filtered in small
scale increments under gravity filtration using glass fiber filters to collect the side product of silver
chloride which is a fine black powder. This process had to be repeated several times in order to ensure no
remaining silver chloride was in the solution. The resulting product remained in chloroform solution, the
silver chloride was discarded. The resulting compound is similar to the aforementioned figure with the
chlorine atoms replaced by a larger and easily cleavable protecting group.

Figure 2.4 Synthesis of cid-Pd complex with triflouromethane sulfonate ligands
A mononuclear ligand was then substituted onto the complex after cleaving of the leaving group.
This reaction took place in the presence of chloroform at room temperature for a 48 hour period with
constant agitation. The ligand was added in a 2.3:1 ratio with the PD complex, as each individual
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molecule required two ligands. The resultant product was then filtered under gravity filtration to remove
the triflouromethane sulfonate that was replaced.
The remaining product was rotovaped and stored in a controlled molarity solution in deuterated
methanol. This allowed for ease of characterization later on as well as optimal storage

Figure 2.5 Synthesis of cis-Pd complex with mononuclear ligand
The compound was characterized using a JEOL 600MHz NMR instrument. As illustrated in the
NMR data that confirms that the synthesis was a success. An initial 31P scan of the compound with the
triflouromethane sulfonate protecting groups shows a single intense peak, this is expected as the phospine
ligands are symmetrical on the compound that would give rise to the single reading (figure 1). When a
subsequent 31P NMR experiment was run on the compound post substitution the same single intense peak
appears and had also shifted, which as illustrated in the literature is consistent with pyridine ligands that
were added (figure 2). Proton and carbon spectra respectively, were also used to assist in the
characterization of the compound (figures 3 & 4).
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The dynamic light scattering (DLS) data illustrates a single population distribution size of
approximately 4600 nm (figure 5). This is consistent with the predicted structure of the compound. It
also demonstrates a successful synthesis with little to no starting material present. These experiments
were carried out in deuterated methanol.
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CHAPTER 3:
MULTINUCLEAR PLATINUM COMPLEXES
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3.1 Summary
The synthesis of a multi-nuclear cis-Pt/Pd phospine complex with long chain lipids was
accomplished. These compounds exhibit amphiphillic properties that allow them to self-assemble in
water as micelles and have remarkable physical properties such as high stability in water. Figure 2.1
shows the molecular structure of the compounds presented in this chapter.

Figure 3.1 Molecular Structure of multinuclear Pt/Pd-complex where M=Pt/Pd and
X=multinuclear ligand
In Moldave (2002), “The dinuclear platinum complexes, similar to cisplatin or
carboplatin, bind to DNA and inhibit DNA replication and transcription, which indicates that
DNA modification by dinuclear platinum complexes plays an important role in the mechanism of
their biological action” (pp. 44). DNA modification seems to be a major plus of multinuclear
platinum complexes which researchers like.
In work conducted by Hud (2009), “[There is] support [for] the original hypothesis that
polynuclear platinum compounds coordinating and modifying DNA in a different way than the
mononuclear complex represent a novel class of platinum anticancer drugs acting by a different
mechanism than cisplatin and its analogues” (pp. 375).
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The cytotoxicity of the multinuclear platinum complex (or its ability to kill cancer) is
very high. According to Clarke, Sadler, and Alessio (1999), “A further determinant of
cytotoxicity is the amount of platinum actually bound to intracellular DNA, which reflects both
the inherent affinity of the drug for DNA as well as the effect of competing metabolic processes
such as binding to plasma proteins and intracellular thiols…” (pp. 112). Thanks to polynuclear
platinum complex research, there is more awareness about the drug cisplatin and its
effectiveness.
Demonstrated in Diederich (2009), “Nowadays there is a marked interest toward
designing cisplatin-dissimilar complexes, which are anticipated to interact with DNA in a
fundamentally different manner and hence to bypass the resistance to the classical platinum
drugs…[one of the most intriguing of which is based] on the development of dinuclear and
multinuclear coordination compounds” (pp. 650). As mentioned before, there is increasing
evidence that multinuclear platinum complexes have greater cytotoxicity than mononuclear ones.
Research conducted in Hong and Chen (2009), “Multinuclear platinum complexes have shown
great potential for cancer chemotherapy. These complexes contain two, three, or four platinum
centers, with both cis and/or trans configurations, and bind to DNA in a manner different from
that of cisplatin…multinuclear complexes [have enhanced cytotoxicity]” (pp. 393).
Several different kinds of complexes exist, but only a few are very effective. As
published by Ram and Bhethanabotla (2008), “Thus, sterically hindered complexes, trans
complexes, multinuclear platinum complexes, complexes with biologically active carrier ligands,
and water-soluble complexes have been studied. In general, platinum (II)- based drugs possess
high affinity for nucleotides” (pp. 271).
Varying ligands are favored for the multinuclear platinum complex, but there are several
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that can be considered effective. According to Abel et. al. (2002), “Many ligand-substitution
reactions of divalent platinum are proposed to involve pentacoordinate intermediates, and there
has been continuing interest in detectable and isolable examples of this class complex. One
[advance] in this area has featured monoalkene complexes of platinum(II), mainly with a variety
of bidentate nitrogen-donor ligands as ancillary ligands” (pp. 542).
What is most important is the understanding of the multinuclear platinum complex’s
contribution to the miracle of modern inorganic coordination chemistry regarding organometallic
pharmaceuticals.
3.2 Goals and Objectives
The goal was to synthesize a multinuclear cis-Pt/Pd phospine complexes with long chain lipids.
These compounds will exhibit amphiphillic properties that would allow them to self assemble in water as
a micelle and in organic solvents as a reverse micelle.
3.3 Synthesis and Design
The synthesis of this compound was carried out in a multi step process. Palladium (II) dichloride
was reacted with 1.3 equivalents of cyclooctadiene in the presence of dichloromethane at room
temperature for 24 hours. The solution was then filtered using gravity filtration. A bright yellow chalky
solid was collected. The remaining solution was then rotovaped to extract any remaining product still in
solution. The total yield was 82%. This gave a cis-Pd complex with Chlorine on one end and
cyclooctadiene on the opposite.
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Figure 3.2 synthesis of cis-Pd/Pt complex with cyclooctadiene
In the second phase, the cis-Pd complex was reacted with a phospine ligand which had four C12
lipid chains attached. Because the phospine ligand was highly hygroscopic and in the presence of air
would oxidize, the synthesis had to be carried out under argon conditions. The reaction vessel was
prepared by using an acetone bath followed by one hour in the drying oven at a constant temperature.
The hot round bottom flask was then removed and set up immediately before allowing it to cool and
accumulate micro condensation. A septum was placed over the flask and one syringe needle was inserted
as ventilation, argon gas was then allowed to flow in via a second syringe needle, since argon is heavier
than oxygen, it was allowed flow freely into the reaction vessel for about thirty minutes, this replaced a
sufficient amount of oxygen, which significantly reduced the possibility for premature oxidation. The cisPd /cyclooctadiene compound was reacted with the phospine ligand in a 1:2.1 ratio in the presence of
chloroform and argon at room temperature for 24 hours. The resulting solution was filtered under gravity
filtration. A crystalline white solid was collected. The filtrate was then rotovaped to obtain any product
remaining in solution. The yield was 74%. The resulting cis-Pd compound now has the phospine ligand
with lipid chains opposite the two Chlorines.
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Figure 3.3 Synthesis of cis-Pt/Pd complex with chlorine ligand
The compound is then reacted with 2.4 equivalents of silver triflouromethane sulfonate in the
presence of chloroform for 24 hours to replace the cis-chlorines with a protecting group, which can easily
be cleaved for later experiments. Because silver is photosensitive this reaction has to be done in a
covered vessel to prevent light from photoreacting the protecting group. The resulting product is filtered
in small scale increments under gravity filtration using glass fiber filters to collect the side product of
silver chloride which is a fine black powder. This process had to be repeated several times in order to
ensure no remaining silver chloride was in the solution. The resulting product remained in chloroform
solution, the silver chloride was discarded. The resulting compound is similar to the aforementioned
figure with the chlorine atoms replaced by a larger and easily cleavable protecting group.
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Figure 3.4 Substitution of Cl ligands with triflouromethane sulfonate
A multinuclear ligand was then substituted onto the complex after cleaving of the leaving group.
This reaction took place in the presence of chloroform at room temperature for a 48 hour period with
constant agitation. The ligand was added in a 2.5:1 ratio with the palladium complex, as each individual
molecule required two ligands. The resultant product was then filtered under gravity filtration to remove
the triflouromethane sulfonate that was replaced. The remaining product was rotovaped and stored in a
controlled molarity of deuterated methanol solution. This allowed for characterization ease later on as
well as optimal storage conditions.
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Figure 3.5 cis Pd/Pt complex with multinuclear ligand
As illustrated in the NMR data there is a confirmation of the synthesis was a success. An initial
31P scan of the compound with the triflouromethane sulfonate protecting groups shows a single intense
peak, this is expected as the phospine ligands are symmetrical on the compound resulting a the single
peak for both (figure 1). When a subsequent 31P NMR experiment was run on the compound post
substitution the same single intense peak appears however it had shifted, which is illustrated in the
literature is consistent with multinuclear ligands that had been added. Proton and carbon NMR
(respectively) were also collected that were used to assist in characterization of the compounds. (figure 6
& 7).
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The dynamic light scattering (DLS) data illustrates a population distribution size of 5200 nm
average (figure 8). This dual population distribution can be attributed to the synthesis not going
completion. It is evident that some of the Pd complex did not completely react leaving some
unsubstantiated Pd complex as well as some fully substituted complexes with the intended multinuclear
ligands. The average size however, is consistent with the predicted size not only of the multinuclear
compound but also with that of the unreacted triflouromethane protected starting material.
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CHAPTER 4:
INVERSE MICELLE
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4.1 Summary of Chapter:
This chapter discusses the novel synthesis of a Platinum centered inverse micelle in
tetrahedral conformation. This compound is designed to self assemble in the presence of an
organic solvent and will have a hollow cavity in the center of defined size. This cavity uptakes a
finite amount of water for low temperature NMR studies. These studies will create and confirm
the presence of water nanorystals in their solid form with a uniform size population.

Figure 3.1 3-D rendering of inverse micelle

The formulation of nanocrystals is important in several areas of scientific research.
According to Vo-Dinh (2007), “The current intense interest in the use of semiconductor
nanocrystals…and related applications can be traced to the 1998 publications by Bruchez et. al.
and Chan and Nie…” (pp. 4-1). One may wonder what inverse micelles are. Simply, as written
by Klabunde (2001), “Reverse micelles are water-in-oil droplets” (pp. 62).
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The formulation of crystals is important to finding a precipitate. According to Zheng et.
al. (2010), “[F]unctionalization of the dendrons and/or the supramolecular core should allow
access to 3-D hollow supramolecular functional systems with potential applications such as guest
encapsulation, nano-reactor, and drug delivery.” (pp. 4749) One aspect of the inverse micelle is
that the experimenter actually has great control in deciding how large to make the particle that
will be distilled. According to Spencer and Moore (2001), “Inverse micelle environments allow
for a great deal of control not only over particle size [and] particle shape…Perhaps the most
severe limitation of the inverse micelle approach is that it can only form nanocrystals whose
precursors are stable and solvated by water…alternative reactions which proceed in dry, organic
solvents are necessary” (pp. 2592).
As stated in Giacomelli (2010): “The micellization process leads to the formation of
ordered structures in which the contact between the insoluble block and the solvent is
minimized” (pp. B). There are various symbols used in helping to follow the chemical reactions
since they large and cumbersome to draw. Physically speaking, according to Feldheim and Foss
(2002), “M is [the symbol for] the metal ion precursor to the nanocrystal material” (pp. 208).
Inverse micelle synthesis basically involves water, oil, and a surfactant. These are combined in
perfect harmony in order to produce a distillation of water nanocrystals.
As stated by Schwarz, Contescu, and Putyera (2004), “The inverse micelle synthesis
[requires the presence of an] ionic metal salt precursor metal salt concentration of 0.01-0.1 M
and surfactant concentrations of ~5-10 wt.% (~0.2 M)[;] there are only about 1-4 precursor
ions/micelle. [Growth] of N=10-10000 atoms must occur via micellar diffusion, micelle
collision, temporary interface fusion, and atomic interchange” (pp. 3179). This is a very
common experiment, which is performed in order to bring about nanocrystals.
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In research of Robinson (2003), “Reverse micelles can be used as nanoreactors to
produce nanoparticles. In most cases, a spherical template produces nanospheres. …hydration
of the water pool, procedure mode and size of the template control the nanocrystal growth” (pp.
27). Microemulsion only occurs when there is larger particles.
However, according to Klimov (2004), which states that, “In general, the reverse-micelle
approach entails preparation of a surfactant-polar solvent-nonpolar solvent microemulsion,
where the content of the spontaneously generated spherical micelles is the polar-solvent fraction
and that of the external matrix is the non-polar solvent” (pp. 13). It is important to regulate the
amount of water placed in the mixture.
According to Mattoussi and Cheon (2009), who indicated that “One can vary the water
content of the mixture to control the size of the water droplets…suspended in the oil phase” (pp.
5). Additional evidence states, in Rotello (2004), “[S]ize control represented a major advance in
the field, due to the critically size-dependent properties of nanoparticles” (pp. 33).
Even more evidence attesting to this fact follows. In the works of Knauth and
Schoonman (2002), “Colloidal solutions are good candidates for controlling the shape of
nanocrystals. For a given surfactant-water-oil system, it is well known that a large variety of
self-organizations of the surfactant can be produced” (pp. ii). The way the nanocrystals are
produced depends largely upon the template that is used in forming the crystals.
As stated by Somasundaran (2006), “The obtained results demonstrate that the water
phase of microemulsions at least partially controls the shape of the produced nanoparticles, i.e., a
template-directed growth exists…[t]he templating effect of elongated water droplets in
the…nanocrystal growth has been…confirmed by…induced formation of silver nanorods and
nonfibers in AOT reverse micelles” (pp. 6194).
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The surfactant that is usually used in such an experiment of inverse micelle synthesis is
AOT. According to Vij (2004), “AOT (sodium dialkylsulphosuccinate)…is especially suitable
for this application as it can solubilize up to 50 moles of water per mole of surfactant. Reverse
micelles of AOT in water have also been used to template the synthesis of CdTe nanocrystals.
[Synthesis happens in] in colloidal solutions containing stabilizers” (pp. 177).
Precipitation or distillation of the nanocrystals is usually the end result of the experiment.
According to Rao, Thomas, and Kulkarni (2007), “Reverse or inverted micelles formed by the
dispersion of water in oil, stabilized by surfactants are useful templates to synthesize nanoscale
particles of metals, semiconductors, and oxides…In order to synthesize nanocrystals, one mixes
micelles made of aqueous metal ions with micelles consisting of an appropriate reagent that can
bring about…precipitation” (pp. 54). The idea of the experiment is to capture the nanocrystals in
a calcified state.
Based on data from Lalena and Cleary (2010), “[Within using inverse micelles, t]he
challenge is to capture the desired size and shape of the particle such that it is preserved once the
template is removed, usually by calcination. In the early 1990s, researchers at
Mobil…showed…mesoporous silicates could be synthesized…using lycrotropic liquid
crystalline phases as the template” (pp. 522).
4.2 Objectives:

An inverse micelle was designed and a novel synthesis created to create a compound with
a definable size hollow center that will readily uptake water when added. This will allow the
study of a defined size water drop in low temperature environments. When taken to a freezing
range the water inside will crystallize and form defined size water nanocrystals.
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4.3 Design and Synthesis:
In a one pot synthesis 9 mg of (L3P)2Pt(OTF)2 were reacted with 1 mg of 1,3,5tricarboxyclic benzene and 1.5 microliters of tri-isopropylamine. This reaction took place in the
presence of deuterated acetonitrile and allowed to agitate at room temperature for 24 hours.

Figure 4.1 One pot synthesis of inverse micelle inverse micelle as product omitted from scheme
,refer to figure 16 in appendix for illustration.
As illustrated in the above figure 4.1 the resultant product is an inverse micelle in tetrahedral
conformation with C18H37 lipid chains extending from each platinum anchor. This compound
has a defined size region in the center that is measurable through DLS analysis.
A controlled amount of water (4 microliters) was added to the compound in solution.
When water was added to the solution an instant emulsion was formed, illustrating the uptake of
water into the micelles hollow center. As illustrated in (figure 9) there is a single population
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distribution in reference to size of the water uptake. This gives inference to the amount of water
present in the micelle.
The NMR studies were the most revealing part of the characterization process. These
were all run on a 600MHz instrument under cryo conditions. A series of proton NMR studies
were conducted at decreasing temperature intervals of 10˚C until a low mark of -40˚C.
The figures illustrating these studies (figure 10-12) are three per page with the original
room temperature run at the top of each for comparison basis. In the presence of chloroform, the
solvent used in these experiments, the water peak appears at approximately 1.5 ppm. It is the
behavior of this peak at the varying temperatures that we are most interested in. Secondly at
approximately 0.5 ppm there is a peak showing bound water that is water which is in solvent. It
is evident that as temperature is decreased the peak increase, this is common behavior at lower
temperatures. As we track the compounds behavior in the freezing environment several changes
of interest occur. It was noted that the intensity of the bound water peak (~4.8 ppm) decreases
significantly over the course of the experiment, while the free water intensity (~2.5 ppm)
increases, over the same temperature range. This demonstrates a shift of water present in the
system out of solution with chloroform and congregating into the single hollow area provided
within the synthesized compound. This trend begins at the -10˚C interval and continues through
the end of the experimental run. With the freezing temperature of chloroform being
approximately -60˚C we were able to go well into the freezing temperature of water while not
freezing the solvent which the compound was present in. This allowed for a focus on only the
behavior of the water and no other liquids in the system. It is also important to note the rise of a
peak that begins to show itself at -10˚C and continues to increase in intensity as the temperature
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decreases. This same peak disappears again as the temperature is increases by the same 10˚C
increments it was decreased (figure 13-15). It is an occurrence that warrants further study.
The compilation of these experiments demonstrates strong evidence for the formation of
water nanocrystals in a controlled and defined size population, after a thorough literature review
this type of characterization has not yet been published in any journal.
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CHAPTER 5:
DISCUSSION

35

The mononuclear compound was well characterized via NMR studies. Once
characterization was accomplished a study into the proposed behavior was conducted. First,
DLS (dynamic light scattering) studies were conducted to determine the population size and
distribution of the compound in emulsion (1% by weight). As predicted there was a uniform
single size population with an average micelle diameter of 4600nm. Under optical microscopy
the micelles were observed in emulsion. This was visual evidence of the mononuclear
compound self assembling in the presence of water via hydrophobic interactions to form said
micelles. Conversely as water was removed from the emulsion to create dehydrated conditions,
the micelles began to dysmorph and break apart into their individual component compounds.
This demonstrated not only confirmation of a discrete supramolecular structure via defined size,
but also confirmation of predicted behavior in emulsion.
The multinuclear compound was characterized in the same fashion as the mononuclear
compound. Again once this was complete a DLS study of the compound in emulsion was
conducted to determine the size and distribution of the micelle population. According the studies
there were two average size populations in the emulsion. While this did not correlate to the
earlier studies of the mononuclear studies, it did not mean the experiment was unsuccessful.
Since the multinuclear compound formed square planar Pt-ligand complexes, the ring stacking
interactions allowed for extended multinuclear structure, meaning they would self assemble into
infinite size supramoleular structures. This was confirmed when the emulsion was viewed under
optical microscopy. It was evident that not only was the emulsion more densely populated with
micelles, it was clear that there was a wide range of size, from those mirroring the mononuclear
complex to some almost 5micrometers in diameter. Again when the emulsion was dehydrated
the supramolecular complex began to dysmorph and break apart into its individual component
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compounds. This confirmed the predicted synthesis and behavior of a extended supramolecular
structure via square planar Pt complexes.
The novel synthesis of the reverse micelle began with a similar compound to the
aforementioned complexes. Pt centered with lipid chains this complex would self assemble in
the presence of organic solvent, this would cause a reverse of the hydrophobic effect, where the
lipid chains would orient outwards as opposed to inwards. This behavior would create a hollow
center cavity of defined size vis a vi the tetrahedral conformation of the structure. Once
characterized the compound was then put in emulsion with a defined amount of water (4
microliters).
The DLS studies showed a single size population distribution of approximately 65nm,
much smaller than the low echelon of visible light, therefore very difficult to observe even with
optical microscopy. The most telling behavior was observed in low temperature NMR studies,
conducted on the JEOL 600 MHz instrument. These studies showed well defined water peaks,
one showing free water, that is water in solvent comprised of individual molecules, and bound
water, that is water hydrogen bonding to other water molecules to form a suprastruture. As
temperatures decreased beyond freezing, the free water peak began to disappear completely from
the spectra as the bound water peak began to sharpen up and increase in intensity. The behavior
of this peak was the inverse of not only the free water peak, but of all other peaks present in the
spectra.
The overall impact of this research is far reaching and widely applicable in
supramolecular chemistry. The novel synthesis of a new class of metal-ligand complexes with
lipid chains brings a new dimension of potential to the current work being conducted in the field.
Furthermore, the ability to easily substitute mononuclear ligands for the synthesis of discreet
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supramolecualr structures as well as multinuclear ligands for extended supramolecular structures
further extends the potential of said complexes. This will allow us to follow the protocol and
create a library of compounds.
This work also highlights the novel synthesis of a Pt centered complex that allows for the
creation of a reverse micelle with a defined size hallow cavity for the creation and study of water
nanocrystals in a confined environment via low temperature NMR studies. The ability to study
water nanocrystals in these conditions has not yet been published in any works to date.
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Chapter 6:
A PERSONAL PERSPECTIVE OF THE
STATE OF CURRENT CANCER TREATMENT
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The benefits of platinum-based anti-cancer drugs cannot go unnoticed. From its very
inception, especially, the drug cisplatin stands out as one of the most major discoveries in cancer
research.
Cisplatin and other platinum-based drugs give people: hope for the present; help for the
present; the promise of a future; and a necessary focus on having a person-centered approach in
curing cancer with regards to palliative care, or end-of-life care and inter-agency working.
When someone comes into the doctor’s office, the last thing he or she wants to hear is the
dreaded “C” word: cancer. Cancer, years ago, was a death sentence. However, today—due to
the advancement of anti-cancer drug therapy and research, including various therapies that can
be employed in the eradication of cancer—cancer is no longer a death sentence. Cancer has
become a treatable illness that people can live with, and, yes, even beat—if they follow a healthy
regimen and continue with all of their necessary doctor-prescribed treatments.
Drugs like cisplatin and other platinum-based drugs give cancer patients, as well as their
families, hope that a cure is possible. And, in fact, studies have shown that people with a variety
of types of cancers have been cured through usage of cisplatin.
Cisplatin has been found to be very effective in the treatment of various types of tumors.
It is not surprising, then, that these various types of cancers can now be cured with the usage of
cisplatin and other platinum-based drugs.
It has been shown in research that cisplatin and other platinum-based drugs retard the
growth of cancer cells. It is of premier importance that this knowledge be taken into account
when doctors are considering which drug(s) to prescribe his or her patient in the treatment of any
kind of cancer.
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These kinds of drugs give cancer patients and their families hope. New research means
that clinical trials can be begun on even newer and better platinum drug therapies which hold the
key to the future. Hope is a valuable resource for the cancer patient, as sometimes the cancer
patient does not have much else. Their time, their money, their resources—all of it is dedicated
to the eradication of cancer.
Families are stressed out by many aspects of having to deal with the patient’s cancer. In
this respect, many families have difficulties with health insurance and providing the right type of
care for their sick family member(s) without even having to deal with the aspect of what kind of
drug or drugs the patient will be taking. Hope is a valuable tool. It can be used to combat stress
in the midst of difficult times during drug therapy. Many times, cancer patients have to struggle
with the fact that they are facing death. Additionally, what makes the experience worse is the
fact that, oftentimes, platinum-based drugs usually cause side effects in the patient.
These drugs do give patients help for the present as well. This, however, can be
overshadowed by the fact that, as aforementioned, the platinum-based drugs can have nasty side
effects that completely turn the patient’s life upside-down. Side effects from platinum-based
drugs vary. The side effects of platinum-based drugs include diarrhea, upset stomach, inability
to eat and drink, and general nausea—among other things. Although the advancement of
science in platinum-based drugs is welcome, one of the areas in which scientists must do a better
job is figuring out how to develop drugs with few or no side effects. This is because, what
happens is that the platinum-based drugs—along with killing cancer cells—kill normal cells as
well.
This precludes a major rejection of the drugs from the body’s system. This “rejection” is
preempted by several side effects, one of which is the feeling of nausea. Usually this nausea is
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so extreme that patients will not want to eat, get out of bed, or basically do anything for long
stretches of time—sometimes days. Generally, cancer patients who are on these platinum-based
drugs also experience weakness all over.
Patients on platinum-based drug therapy will generally not want to do much. They are so
greatly weakened by the therapy that they will have to forego other activities they might have
liked to do. Cancer patients must undergo some temporary pain on these platinum-based drugs
in order to receive help for their situation. Although it is not very palatable, they must undergo
this difficult process in order to live a normal, healthy, productive life. Help for the present has
come in the form of these platinum-based anti-cancer drug therapies. Although cancer patients
may have to endure much suffering, basically it is to their credit that they can pull through these
trying times in order to live a better life.
Platinum-based drugs like cisplatin are definitely allies in the race to find a cure for
cancer. Physicists, chemists, and biologists should all take note of the fact that there is already a
cure out there—it just has to be perfected in order to help the patient more.

Platinum-based

drugs can be perfected in order so that there are not as many, or no, side effects. However,
scientists must figure out how to make the drugs target only abnormal, unhealthy, and/or
cancerous cells. Scientists must figure out how to stop these platinum-based drugs from
targeting healthy cells while killing cancerous cells. If they can do that, they will revolutionize
cancer research. As it stands today, the drugs that are being developed in order to combat cancer
have horrible side effects. For the most part, this is the worst part about being a cancer patient.
Every cancer patient most likely dreads some aspect of their therapy that will eventually
make him or her sick—so sick that illness will impede him or her from doing things they would
do in everyday life. Whether it is chemotherapy, radiation therapy, or platinum-based drug
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theory (in combination with a variety of other drugs)—the bottom line is that the cancer patient
is going to have to go through some suffering in order to be healthy again.
That is the bare reality of cancer treatment today. It is a very hard road to hoe on the way
to being cancer-free. However, those drugs are what represent, in a very tangible form, the key
to a cancer patient’s survival. Therefore, other such drugs that are platinum-based should be
researched until there is a definitive cure for cancer that is found. Help for the present is
available in the form of these platinum-based drugs. Although it is frustrating that these drugs
have visible side effects, everything that is in scientists’ power should be done in order to search
for the cure for cancer.
Obviously, cancer research needs funding. Help for cancer patients may be found in
continuing to raise awareness about the illness, as well as having annual funds, drives, and walks
in the hopes of raising money for research, which can be life-saving. This type of research
should be supported all across the United States and elsewhere in the world, as cancer is one of
the leading killers worldwide. The morbidity rate for different cancers varies depending on what
type of cancer one has.
Still, researchers should continue being dogged about the way they approach research.
They could possibly save their grandchildren from ever having to worry about dying from the
awful fate of cancer. What will help cancer patients the most are the fundraisers and the
researchers who are doing everything in their power to contribute to the fight against cancer.
They are, respectively, raising money for research and probing deeper into the causes and cures
of the illness itself.
Hopefully, the help for the present, in the form of cisplatin and other platinum-based
drugs, can assist in deterring and curing cancer on a short-term basis. On a long-term basis,
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however, one must look ahead toward the promise of a brighter future with therapy that heals
completely. The promise of a new tomorrow awaits. Steadily, researchers are making progress
in the arena of cancer research. For some people, finding the cure will come too late.
For others, however, this could be the major key to their overall health and well-being.
It is important to realize that no one should ideally ever have to face cancer. They should ideally
not have to worry about knowing if they are going to ever get well again or not (by going into
remission). Dealing with cancer is difficult, but the hope is that research will continue making
new advances. Scientific discoveries will only continue to ameliorate the problems cancer
causes.
Ultimately it is hoped that a cure for cancer will be found. Since cancer is one of the top
ten killers in the United States, it is hoped that cancer will someday be largely a thing of the past
and will be eradicated. The promise of the future is that cancer will one day, indeed, be an
illness which no one needs to worry about contracting because it will be curable.
However, as things currently are, there remains no single effective cure for cancer.
As such, fundraisers and researchers must remain dogged in the pursuit to eliminate this illness
from the face of the earth. It can be done, if people just focus on trying to make breakthroughs in
both the raising of money for research and the actual research needed to rid the body of the
disease.
On the part of fundraisers, this means being vigorous in assuming that almost anyone can
contribute to the fight to end cancer. People should be made aware of how important it is to fight
cancer, and how this can affect all of us in terms of hurting people we know and love.
Fundraisers must realize that every dollar that goes towards cancer research is a dollar towards
ending the grips that cancer has on peoples’ physical bodies.
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Researchers should also realize how precious time is, and that so many people do not
have much time left, due to the fact that there was not good research in place when they got
cancer. The promise of the future is that no man, woman, or child will have to live with cancer.
It will be a happy day when that happens. Researchers also play roles, too. Researchers should
dedicate themselves wholeheartedly to the cause of finding a cure for cancer.
Researchers should find employment in sectors where cancer research is funded.
Researchers should be encouraged to find jobs where they are, in turn, pushed and prodded to do
research that will save lives. This does not necessarily have to be about finding the research for
cancer only. They can also look for cures for other diseases in the process. However, cancer is
such a common illness that this should be the main focus of the push to end cancer. In order to
do this, researchers should be encouraged to dedicate themselves to eliminating a major disease
throughout their lifetime.
Two decades ago, it was the practitioners who had been dominating the health and social
care environment with the patients/service users being placed at the lower end of the spectrum as
passive takers of such services. This has been gradually shifting, thanks to the approach of the
Government, whose rhetoric now promotes the principles of choice and control for service users
within a seamless service. This has brought in a paradigm shift in the delivery of health care
services, wherein, the earlier 'professional directed approach' is being replaced by a 'personcentered approach' which demands practitioners to tune their thinking and implement practicing
to the needs, desires and the rights of the users of health care services.
A major challenge this writer poses need to be highlighted. It relates to 'jargons and
terminologies.' For instance, from a practitioner's point of view, the term 'patient' has been used
in a generic fashion, which does not gel with the way midwives or social workers may use it.
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To midwives, there has been an extended meaning to such terms as women- or childcatered care to include their families. In the same manner, social workers more often use the
term ‘service users/careers’ whereas the occupational therapists treat them as their 'clients.’ For
the purposes of this paper, the definition of Overetveit et al. (1997) produced herein under is
taken:
‘If one of the purposes of interprofessional working is the combining of different
perspectives then the patients or service users are interprofessional workers par excellence
[since] they...unify and combine the different advice and perspectives integrating them into daily
living and making health choices as they do so” (p.117). This approach centers around five
theoretical concepts, as identified by Leventhal and Cameron (1987) that are considered to be
relevant to this paper, which are: (1) bio-medical; (2) behavioral; (3) communication; (4)
cognitive; and (5) self-regulatory.
In the bio-medical theory as elsewhere pointed out in this paper, the patients are taken to
be passive recipients of doctors' instructions; the absence of good health or presence of disease is
traced to bio-medical causes and the treatment is based on the patient’s body. The solutions are
mechanical reflected in a prescriptive regime, and the non-adherence to treatment is traced to the
physical characteristics of the patient. A major limitation of this theory is that it takes into
account only the patient characteristics that may impact their health behavior. The behavioral
theory places emphasis on the learning perspectives and focuses on the environment and the
teaching of skills to manage adherence.
It treats behavior as a product of antecedents which could be arising out of internal or
external factors, as thoughts and environments respectively and the consequences of them could
be reflected either in the form of punishments or rewards. The limiting factor of this theory is
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the lack of an individualized approach and also the tendency in not taking into account the
factors that consciously influence the behavior that is not linked to immediate rewards.
Communication theory places the emphasis on patient-practitioner relationship and is based on
patient education and good health care worker communications skills. It further relies on three
factors: treatment, instruction and comprehension.
In this context, the academicians and researchers have started to emphasize the concept of
‘narrative-based medicine’ to promote the physician-patient based communication that is found
to promote the physician-patient based communication and enable a better outcome on the health
of those undergoing treatment. The principle behind this concept is the emphasis that is laid
down on the information-sharing between the two during the medical interview, and such a
perspective—though the research has supported to have positive outcomes…—has been found in
reality to be lost.
Major criticisms of this theory centre on its not taking into account attitudinal,
motivational and interpersonal factors that may interfere with the reception of the message and
the translation of knowledge into behavioral changes. Nevertheless, among all the approaches,
this is considered to be the cornerstone of every patient-practitioner relationship and most
relevant to this paper and of late more and more reviews are being undertaken to determine the
effects communication elements. The cognitive model bases its arguments on a number of subelements, the chief among which are health-belief, socio-cognitive factors, reasoned-action,
planned-behavior and protection-motivation.
The health-related behavior is based on certain attitudes, beliefs, the outcomes of the
expectations based on a futuristic perspective. The basis of these approaches suffer from the
weaknesses of not accounting for non-voluntary factors that could affect behavior, sub-optimal
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outcomes from a cost-benefit analysis, power relationship and social reputation. According to
health belief theory, health behavior is based on the outcome of a rational appraisal that is
arrived at through a balancing of barriers to and benefits of action. It relies on the demographic
and socio-psychological variables to construct the barriers and benefits. The threats to health
and benefits out of the outcomes of the treatment are the major factors that influence the
behavior.
This theory is criticized, firstly, for the lack of empirical evidence of the relationship
between the variables and secondly, for the non-inclusion of social influence. Self-regulatory
theory focuses itself on the patient, advances that it is imperative to examine the individual's
subjective experience of health threats to understand the manner in which they adapt to these
threats and they form the cognitive representatives of health threats by committing new
information with past experience. Its central theme is that people, by engaging themselves into
active and self-regulating behavior, are the problem-solvers of their illness. The main criticism
relating to this theory is that it is more intuitive rather than evidence- based.
These theories can broadly be reduced into two philosophies which currently drive the
interprofessional practitioner-patient models, which are the medical and social models. The
medical model relies on the belief of medical experts in that they know what is the best for their
patients whereas the social model lays emphasis on issues of power in the professional role and
though curiously looks at as to how the 'helping' relationship can also prove to be disempowering
and produce a level of dependency on the professional.
Inter-agency working (IAW), put in another way, is nothing but collaborative working
which has the support of those who have seen for themselves the advantages of working with a
diverse disciplines in a person-centered care. At the same time, interprofessional working also
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calls for a significant reorientation of professional working practices. If this be the case, one has
to focus at finding out what are those factors that govern the interprofessional working.
Awareness at work, both at organizational and interpersonal levels—which falls under the
academic psychology—includes the structural issues that weave around various elements of the
players.
Both practitioners and users involved in the health sector have to face the cultural issues
including anti-divinatory practices, whether based on religion, sex and or age, which are some of
those important factors. The plays of such factors also imply a shift from patient-to-person
entered care. However, with regard to palliative care, there are two theories which may be
appropriate for being mentioned here. The “Praxis Theory of Suffering” focuses on the
Behavioral-experiential nature of suffering.
Here, suffering is perceived as comprising of two behavioral states, enduring and
suffering. Enduring is characterized by suppression of emotion whereas in the other case, it is
manifested in a state of distress in which the emotions are released. The complexity theory
compares the palliative care to the physical, biological and social systems. As they have been
found to have relevance in those areas as broad as meteorology, biology, organizational theory,
etc., the same is also being applied and evaluated in order to find its relevance to the field of
palliative care.
If this is the development that has been taking place in the health sector, which places
emphasis on social care, it is imperative to consider its implications from a theoretical and
practical perspective and that is the central objective here. It would critically explore the values
and concepts of Inter-Agency (IAW) approaches with specific reference to palliative care.
Ethike is a Greek word from which the word ethics is derived. Ethos is a value which one has
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and consistently applies to one’s life. Within the palliative care setting, there are three aspects of
patient care that need special attention: the realms of the palliative care patient; the realm of the
palliative care nurse; and the realm of the palliative care team.
The realm of the palliative care patient is mainly concerned with the patients’ well-being
even though he or she is in the end stages of terminal illness. The patient is still given treatment,
in most instances, for what ails him or her, but the patient is prepared to die at any moment.
Thus, palliative care focuses on maintaining a sense of homeostasis within the patient even
tough; unfortunately, the patient is ultimately most likely going to die of his or her disease in
most cases instead of being discharged from palliative care.
It is important to remember when dealing with a palliative care patient is that there are
many things that a supportive caregiver or family member should, as well as should not do.
Therefore, people must be sensitive to these areas of the palliative care patient’s psyche which
could be easily damaged. First of all, the palliative care patient does not want to be lectured;
especially, it is important not to blame a patient for his or her illness. For example, saying things
like, “Well, if you hadn’t smoked all your life, you wouldn’t have gotten lung cancer.”
Or, someone might be thoughtless enough to say something like, “If you had eaten
healthier earlier in life, you wouldn’t have had…” fill-in-the-blank—chronic health problem X,
Y, or Z such as heart failure, diabetes, cancer, etc. Additionally, if a palliative care patient has
cancer, it is tempting to want to demonstrate Lance Armstrong Syndrome. The idea that if a
person has a strong mind and a positive mental attitude (PMA), one will overcome cancer—is an
illogical fallacy. Although there is indeed much debate about “mind over matter” in medicine,
the bald truth is that cancer is a very tangible problem which cannot simply be overcome by
someone just willing it to be so with the power of one’s mind.
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Truly, a positive attitude is not the only thing that one must have in order to beat cancer.
One also must have the biological predisposition to overcome the cancer. In other words…if the
underlying pathology of the patient suggests that he or she will continue to be ill, that is exactly
what will happen, and he or she will not be able to overcome the illness by simply willing it
away—no matter how strong their psychic faculties be. One fundamental flaw about people
with Lance Armstrong Syndrome is that they assume that someone must be weak-willed or
having lack of fortitude of mind if they cannot overcome cancer by simply having a positive
attitude. This is, again, an illogical fallacy.
Now, clearly, there are people who are of the philosophical bent which ascribe to the
theory that one can overcome illness by simply having enough faith. Again, this is also an
illogical fallacy which may be difficult for some to overcome. However, it is a must that people
heed the fact that not everyone is going to be a cancer survivor. Realizing this fact is facing
reality.
Sometimes people are not realistic in their assessments, i.e., dealing with their relatives
who are in palliative care. For example, they may think mistakenly, or perhaps, were led astray
to believe, that their loved one, if cared for enough, would somehow miraculously recover.
Many family members of patients who are in palliative care mistakenly assume, many times
wrongly, that their loved one will indeed get better. However, sadly, this is usually not the case.
What is common is that the patient’s condition deteriorates, and the family is suddenly
caught in arrears because, unfortunately, they have a difficult time accepting the inevitable—the
fact that their loved one is dying. This is the phase of the dying process called denial. They
slowly then come to acceptance after having just been in disbelief. They then move to denial and
then acceptance.
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Unfortunately, the family may have a more difficult time than the patient. The family has
a difficult time basically because they are the ones who are left behind to contemplate the
meaning of life without their loved one. In essence, funerals are then, not for the dead but for the
living. Truly, it is possible for someone who is dying of cancer to overcome his or her illness.
But, for a family to hold on hope that their loved one will definitely get better is a false hope in
palliative care practice settings. Understandably so, palliative care nurses must be continually
assessing and evaluating the needs of the palliative care patient. Are the patients’ medications at
the correct dosages? Do they need to be adjusted?
The duty of the palliative care nurse is to continuously be monitoring a patient’s relative
progress or the lack thereof. A palliative care nurse, if there is any significant change in the
patient’s status (positive or negative) should make notes of this in his or her care plans and make
contingency plans to provide for any changes in temperament in the patient. The duty of the
palliative care team is to reassure that all the patient’s needs are coordinated.
Usually a palliative care team consists of: the nurses that are working on all of the
palliative care patients; the main doctors which oversee the palliative care setting; the social
worker; the chaplain; and perhaps most obviously, the family and/or caregivers. It is the duty of
the palliative care team on the end of the hospital or other organization taking care of the
patient—not now speaking of the family and/or caregivers—that they establish a sense of trust
and reliability with the patient. Since the palliative care nurse is the person who will have the
most contact with the patient, it is of maximum importance that the nurse be professional,
respectable, and affable.
It is the duty of the other nurses to patiently listen as each individual nurse expresses his
or her reflections on the progress of the patients. Similarly, it is the doctors’ duty to reflect on
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how the status of the patients is. The social worker is available in order to address any issues
that might come up regarding the patient’s living conditions, environment, etc. The chaplain is
available in order to help out with a patient’s spiritual needs.
In any case, the palliative care team is very important, and of course, one cannot forget
the importance of the role of the family and/or caregivers, which must work with the hospitals or
organizations palliative care team members. The palliative care team works together to provide
the service of helping the patient through this troubling and complex time in his or her life.
Hopefully the team can make that patient’s journey an easier and perhaps less stressful one.
The skills needed for interagency working in palliative care are as follows. The demand
for palliative care education for generalists would grow along with the spread of such a care.
Provisions hence would have to be made for the practitioners, irruptive of their fields of
specializations, to have easy access to courses and short term clinical attachments. Within the
general education, there has to be more emphasis on 'modular education,' especially for the
nursing professionals.
With the advent of the Internet and technological developments, more reliance could be
placed on distance-learning which can further be accelerated by especially providing such
facilities by catering to the needs of those working in residential homes. At a higher level,
institutions of higher learning could augment the facilities by creating professional chairs in
medical, nursing and social work.
As pointed out elsewhere in this paper, the current paucity in research could be made
good if funding bodies and pharmaceutical industries recognize the relevance and need for
palliative care.
A vast magnitude of the population in the UK, for example (over 2,300,000) is reported
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to be afflicted with cancer. Patients and their families face shocks, uncertainties and need
support at all stages. Though such a support was available, it was revealed that there were still a
considerable number of such patients who stated that they did not receive the information and
support they needed. All the more showed considerable variations in the quality of care
delivered across countries. One of the reasons for this was attributed to the poor
interprofessional communication and coordination.
Several different agencies have been directed to and engaging themselves in and
developing standards, having realized that effective face-to-face communication between health
and social care professionals is important, on the one hand. Patients and caregivers, on the other
hand, are fundamental to the provision of high-quality health care. In practice it was found that
much of the professional support furnished to the patients afflicted with advanced cancer was
delivered by non-specialist social and health care professionals in palliative care, which has been
an area of concern. In this regard, it is indicated that there is also a paucity of literature and in
order to fulfill this gap, it is widely perceived that budgetary provisions should be enhanced.
The disparities in the provisions of the palliative care around the world have given rise to
a new genre of rhetoric in that it is seen as a human right belonging to the arms of international
law. So much of rhetoric dominates the literature about the entitlement of people needing
palliative care in the name of human rights, but, when removed from such rhetoric, the realities
which remain are totally different. This is explained with reference to one sensitive topic, i.e.,
assisted suicide.
Compassion and the right of the patient to die are two commonly-presented reasons in
favor of the concept of assisted suicide. Emotions are wrought by the usage of compassion
because of its universal appeal. But when divorced from emotions, it would become clear that
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compassion can be distorted and harmful. In this particular case, the human beings would be
deprived of their dignity, and in effect it would mean their being killed.
It may be a moral reason for relieving the humans from the sufferings that terminal
illness brings on them, but, not a moral justification for ending a human life. In effect, while
handling terminally ill patients needing palliative care, the leaders of governance, policy-makers
and the practitioners all should remove themselves from such rhetoric. People should engage
themselves in efforts that would make such a life as comfortable as possible without injecting
further sadness into them. These are the effects of good palliative care and interagency working
with people who have cancer.
Multi-professional working is looked at as a driver of social inclusion, but, the problem is
the policy directives are considered to be running ahead of conceptualization. This is especially
so in as minimal attention has been considered to be paid to conceptualizing the forms of
professional learning that is required to expand the interagency practice and there does not seem
to be any theoretical backing in the practical implementation of inter-agency work. This paper
deals with some of the concerns that have come into focus in this regard.
Many governments since at least the turn of the 21st century have been giving priority to
tackling social exclusions, which are defined as the loss of access to life chances that connect the
individuals to the mainstream of social participation. Interagency collaboration is seen as a
vehicle to achieve such social inclusion which is seen in the initiatives taken by various
governments. While at policy level multi-professional working is seen as a 'self-evident good,'
problems have cropped up in both strategy and operation.
The inter-agency model of working rests upon ‘non-conflictual’ models of collaboration,
but, in reality it denies the tensions that exist between different agencies both at vertical and
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horizontal levels. Moreover, the problems have been identified and discussed by confining them
to managerial or technological issues ignoring the human factors. The conceptual framework
obtaining at present places minimum emphasis upon the need for agencies to learn the working
something as a 'learning process' in which there are as much tensions and difficulties as insights
and motivations.
Of particular concern in this regard is the tendency to use partnership and participation in
an interchangeable manner. It is indeed considered, a pitfall, if one were constrained to use that
term, that to pursue post-bureaucratic analyses of professional practices. This is more than
reflected in the current practices followed to prevent 'social exclusion'. For instance, a single
child in the current scheme of things may have to encounter multiple agencies spanning the
education, health, social services and similar but multifarious agencies that have the effect of
only exacerbating an already existing contentious relationship.
Effectiveness is equated with the containment of distribution to a moderate form and
diminution of conflict. Thus, nothing is resolved, in effect. There is perceived to be an
organizational ambivalence in the inter-agency working both at the vertical and horizontal forms.
They are considered to impede the development of inter-agency working as the practitioners
working at operational level regard barriers to develop in inter-agency approaches within small,
short-term projects as irresolvable in a situation where the mainstream service remained divided
at the top level.
In a setting of this type, the senior level commitment to the multi-professional agency is
considered to remain only at a rhetorical level on account of the fact that overarching
departmental structures remain insulated from one another.
The effect of this is that there is a wedge between micro and macro levels of
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collaborations. While at the micro level, there could be innovations that remain truncated as they
are isolated in the macro level. The working practices did not sustain in the case of short term
projects as there was no mechanism for offering the expertise of the multi-agency professionals
to subsequent inter-agency projects. The inter-agency working is also considered to promote the
emergence of new hybrid professional types which has resulted in the creation of ‘fluidity of
roles’ in which the practitioners have wade through a number of boundary issues.
These may either be internal or external or a combination of both of them. It also poses
problems of cultural change. The areas of concerns could then be summarized as the ones that
relate to the conceptualization of inter-agency working, which places multiple demands upon the
practitioners and clients (patients/careers). In this context, interagency working cannot be
construed as a virtuous solution and or an ideal model of service delivery. It is also equated with
'partnership' tools and considered suitable for analyses of collaboration.
The origins of Integrated Care Pathways (ICPs) or the Clinical Care Pathways as it is
known in the recent literature could be traced to the USA. It is developed by a multiprofessional team involved in the caring process, has to be based on evidence and should follow
prescribed guidelines. It deals with the process of care that is delivered in a given clinical
situation. This has proven to have major success within palliative care practice. It sets the role of
each health care professional in the care of the patient and the caregivers and the details of the
expected outcomes which are recorded on the ICP.
As and when the expected outcome is not achieved, then the reasons for such an outcome
are documented and such deviations are termed as ‘variance’. It is through a review of such
variances future educational needs would be identified which in turn would help in the
improvement of health deliveries in the future. ICPs thus in effect are a dynamic in nature and in
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being done over and over one document may replace another which process may continue until a
central coordinating document emerges.
The applicability of ICP in palliative care rests on the principle of holistic care in which
the patient and careers are involved. While it does not prevent the delivery of individualized
care, it simultaneously allow for the clinical freedom to furnish care within an evidence-based
setting. In a palliative care environment, it has the effect of acting as a multi-professional
document which the professionals can use to coordinate and record the care of the patient. This
includes EMRs (electronic medical records). Its ascendancy to prominence everywhere is of
recent origin. The current emphasis in this regard focuses on interprofessional education which
departs from the earlier multi-disciplinary approach to education. The critical pathway in this is
collaborative practice.
This implies that the Inter Professional Education (IPE) aims at involving the
patients/service users and careers as experts. In essence, caretakers must be experts in order to
know what kind of care to give to their clients/patients. The implementation of the various
frameworks and their expansion into covering more diseases has heightened the need for
collaborative working between health and social services that would ultimately bring in a holistic
approach to patient care. Primary care in this connection has been identified as the key driver in
the implementation of the frameworks.
In regard to the development of the critical pathway, this again is seen as involving the
whole workforce in the provision of first-level care. In other words this is described as an
‘interprofessional framework’ or tool. This implies for the critical pathway further to develop
interagency working would bring in innovations in patient care. This would be obvious.
While the importance of an education program in an ICP is over-recognized, yet in
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practice, it is underachieved. One common reason for this is the excessive workload of the
professionals and exposure to theories in them do not bring in any change in the practices. This
is because implementing an ICP demands a major commitment in terms of time because of the
need to comply with a lengthy procedural requirement.
Nevertheless, this does not in any way undermine the importance of developing and
implementing an ICP, as if the health practitioner community as a whole is familiar with such
tools as and when they commence their entry into the profession, they would usher in a powerful
model for delivery of care. Clinical pathways thus bring in a refreshing approach to the
dissemination of clinical excellence in palliative care. Within it one can develop a number of
sub-models that would address specific requirements. This may help the patients in breathing
their lasts in a dignified environment. It also contains the potential to set standards and for being
used in quality assurances within a palliative care and or hospice setting. It also sets in motion a
change in the mindset in the culture for the care of dying.
In essence, the critical pathways should and would lay emphasis on the delivery of a
multitude of national priorities through networks and collaborations across the board that would
include social care, local government, voluntary and independent sectors. Partnership working
would call for working not only across agency boundaries but also professional boundaries. Of
particular concern in this regard is the tendency to use partnership and participation in an
interchangeable manner. It is indeed considered, a pitfall, if one were constrained to use that
term, that to pursue post-bureaucratic analyses of professional practices. This is more than
reflected in the current practices followed to prevent 'social exclusion'.
For instance, a single child in the current scheme of things may have to encounter
multiple agencies spanning the education, health, social services and similar but multifarious
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agencies that have the effect of only exacerbating an already existing contentious relationship.
Effectiveness is equated with the containment of distribution to a moderate form and
diminution of conflict. There is perceived to be an organizational ambivalence in the interagency working both at the vertical and horizontal forms. They are considered to impede the
development of inter-agency working as the practitioners working at operational level regard
barriers to develop in inter-agency approaches within small, short-term projects as irresolvable in
a situation where the mainstream service remained divided at the top level.
In a setting of this type, the senior level commitment to the multi-professional agency is
considered to remain only at a rhetorical level on account of the fact that overarching
departmental structures remain insulated from one another. The effect of this is that there is a
wedge between micro and macro levels of collaborations. While at the micro level, there could
be innovations that remain truncated as they are isolated in the macro level.
The working practices did not sustain in the case of short term projects as there was no
mechanism for offering the expertise of the multi-agency professionals to subsequent interagency projects. The inter-agency working is also considered to promote the emergence of new
hybrid professional types which has resulted in the creation of 'fluidity of roles' in which the
practitioners have wade through a number of boundary issues, that may either internal or external
or a combination of both of them. It also poses problems of cultural change.
The areas of concerns could then be summarized as the ones that relate to the
conceptualization of inter-agency working, which places multiple demands upon the
practitioners and clients (patients/careers). In this context, interagency working cannot be
construed as a virtuous solution and or an ideal model of service delivery. It is also equated with
'partnership' tools and considered suitable for analyses of collaboration. The natural question
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that crops up is that, “If the interprofessional working is a concept that is confronted with so
many practical problems where its role in the health and social care system is, then what purpose
does it serve?”
This section of the paper would argue the case in general and not relating to palliative
care alone as the picture is to be seen in a broader perspective. In any context, it is seen as a
remedy to the past failings of the health care system. It is something which would bring in
sweeping changes in the delivery of caring in regard to at least that section of the population
which needs it badly, namely, the adolescents.
It is of concern to note that mortality is still predominant in adolescents when compared
with other groups with accidents and self-harm reported to be claiming as major causes of loss of
lives. They also undergo significant mental health problems. The present mental and health
services for children everywhere are seen to be inadequate to cope with their problems. There is
also a diminished level of attendance by them to health care services. The reasons mentioned
above are sufficient to bring in the point that there has to be better methods to attend to their
health care needs. In a primary care setting, they relate to access, confidentiality, consent, and
privacy. Young people have felt that they face barriers to the effective use of both primary and
secondary health care services.
They pertain to lack of information, unfriendly services, sandwiched either with the
children or elders in the hospitals and, in short, health services would have to pay greater
attention to the special needs of them if the delivery health care aims at improving the emotional,
psychological and physical health of the population. These solutions should be innovative, and
also evidence-based.
Demographically, they are not a homogeneous group and have diverse special needs that
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are associated with gender, ethnicity, social and educational disadvantage. The fact that services
for young people with psychological and mental health problems have not changed much in the
last three decades or so makes the introduction and implementation of interprofessional working
an imperative if their requirements have to be met. This is all the more warranted because a
single style of service may not attract the young people. As a result, specific local health service
provisions should take into account all other relevant service provisions including the one that is
multi-professional in nature.
The practitioners involved in such facilities should also be trained to take into account the
specific needs of young people. The quality assurance standards should also be maintained. The
development of the communication skills by the staff is considered to be of paramount
importance and it yet another reason as to why interprofessional agency approach is advocated.
The amount of people dedicated to finding the cure for cancer is going to proportionately affect
how much the illness can be eradicated. If there is a critical mass of people dedicated to ending
cancer forever, then the likelihood is that cancer will not be here to stay. With the advent of all
the new technology, it is very possible that someday a cure will be here. However, having to
deal with many issues, researchers may not be necessarily prepared or as well-funded as they
should be in order to help aid them in their discoveries.
Cancer research must be better-funded and more publicly-supported. If it were, this
would aid a great deal in helping cancer research come to the forefront of issues in the medical
community.

What is such a shame is that any illness is indeed curable if the cure is out there—

if there is a formula, if there is a recipe, it can be done. We just need to find it.
The fact that these platinum-based drugs can give the cancer patients and their families
hope for the present, and a promise for a brighter future in a cancer-free world—this is what
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makes their value priceless. This is because no value can really be placed on human life.
Truly—when one thinks of one’s friend, one’s father, one’s sister, one’s mother, one’s cousin,
one’s brother—no one can replace those people in a person’s family. No one person can be
replaced. Things and places can be replaced, but people can’t.
What people must realize, in order to get people more active and aware within cancer
funding and research, is that their loved ones’ lives may someday be in jeopardy, and they can do
something to prevent that from happening. If people could see into the future and automatically
know that one of their friends or family members was going to get cancer, perhaps they would be
more inclined to be involved and active in the fundraising and the research for finding a cure.
The need for funding and research within the fight against cancer is very real and urgent.
Without funding, there will be no advanced research occurring in the field of anti-cancer
drug therapy. Without advanced research occurring in this field, whole bodies of knowledge will
be lost over time. The longer research is left unattended, the more the theories get stagnant in the
minds of researchers. While this research is new and fresh on researchers’ minds, we should
take advantage of this fact. While this area of research is still very popular, we should strive to
make sure that it reminds high on the list of priorities of fundraisers and researchers around the
globe. One can raise awareness in all different kinds of ways. For example, having social events
that target raising money for cancer research is great ideas in order to both raise awareness and
foster social networking.
Social networking is another wonderful idea in order to further one’s cause. The use of
Facebook and Twitter in order to get the word out about the importance of cancer research and
funding to go towards it may be blogged about, written about on a status update, or be given a
fan page in order to raise awareness (and cash) for research.
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What is amazing is that one can use one’s social networking influence online in order to
influence ordinary events. There is one person on Twitter by the name of Drew Olanoff who
started a revolutionary hashtag (or conversation thread) on Twitter called #beatcancer. Since
Mr. Olanoff started the hashtag #beatcancer, he has raised millions of dollars for cancer research
singlehandedly. This was an idea that he came up with after having been diagnosed with, and
later beat, cancer. Not everyone is as lucky in his or her fights with cancer. Wonderfully,
however, there is now much more money that was donated to cancer research due to Mr.
Olanoff’s selfless efforts. With the continued raising of awareness and an encouragement that the
medical community do more in the field of cancer research, it is hoped that someday cancer will
be known as the curable illness that was once considered incurable.
Mononuclear platinum square complexes, multinuclear platinum complexes, and inverse
micelle synthesis are all important in understanding biological functions better. In the case of
platinum complexes, one can better understand the intricacies of cancer research. With the
advent of cisplatin, platinum drug research became all the rage starting with Farrell’s discovery
in the early ‘90s. After that, the usage of cisplatin exploded, as platinum-based drugs were
vaunted into the spotlight, cisplatin having had marvelous success in clinical trials and in usage
on actual patients after the clinical research was complete.
The benefit of knowing how different compounds do work under certain circumstances is
priceless. Countless lives have been saved, and can continue to be saved, with the development
of cancer research. If it were not for the contributions of thoughtful and energetic scientists, we
might not have the advances in inorganic coordination chemistry that we do today. However,
thankfully, due to the work of Nicholas Farrell and others, we can safely say that we are on the
road to finding definitive cures, or the cure, for cancer.
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That day where the cure for cancer is found has not come yet, but it is fast approaching.
One day people will not have to worry about getting cancer because it will be a curable illness.
Until that day, however, we will have to depend upon the fundraisers to raise money for
cancer research. We will have to depend upon the physicists, the chemists, and the biologists, in
order to help coordinate knowledge and develop new kinds of drugs, both platinum-based and
non-platinum-based. We need to use our collective knowledge in order to make a better
tomorrow for our children today. In order to defeat cancer, we must realize that the difficulties
we face are small if we just collaborate more.
For the scientific community, curing cancer will be its greatest accomplishment and will
be no small feat. With determination, hard work, and research, the cure for cancer will someday
no longer be just a dream but will be a reality.
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